MARCHF5 and cancer: Activation of ISR by a combined treatment of cancer cells with Navitoclax, that acts through B cell lymphoma extra-large (BCLXL) blockade, and protein kinase inhibitors induces MARCH5-mediated ubiquitination and proteolysis of the BCL2 family apoptosis regulator (MCL1).